*Department of Sexuality Studies, San Francisco State University, San Francisco, CA
†Department of Medicine, University of Washington, Seattle, WA
‡Department of Epidemiology, University of Washington, Seattle, WA
§Department of Public Health—Seattle & King County, Seattle, WA
‖Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA
Correspondence to: Joanne Stekler, Box 359931, Harborview Medical Center, 325 Ninth Avenue, Seattle, WA 98104 (e-mail: email@example.com).
The authors have no conflicts of interest to disclose.
Supported by National Institutes of Health, R01 MH086360. Alere provided Determine HIV 1/2 Ag/Ab Combo tests and controls for investigational use. This test is not available for sale in the United States.
Presented in part at the 2011 National HIV Prevention Conference; Atlanta, GA; August 14–17, 2011 [abstract #1595].
The views expressed in this article are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.
To the Editors:
Recommendations from the Centers for Disease Control and Prevention promote routine HIV antibody screening and more frequent targeted testing among high-risk populations.1 Unfortunately, strategies limited to antibody detection cannot identify highly infectious persons with acute HIV infection.2,3 These missed diagnoses represent lost opportunities to link persons into care and reduce the contribution recently infected persons make to ongoing transmission.4–11 In response, some public health programs began pooled nucleic acid amplification testing (NAAT),12–16 increasing costs, laboratory complexity, and turnaround time for test results.
Conversely, point-of-care (POC) HIV tests trade off rapid turnaround times and ability to provide results to more persons17,18 in exchange for a low sensitivity during the “window period” comparable with earliest generations of enzyme immunoassays (EIAs).19–22 In Seattle, the OraQuick ADVANCE Rapid HIV-1/2 Antibody Test (OraQuick, OraSure Technologies Inc., Bethlehem, PA) detected only 91% of antibody-positive men who have sex with men (MSM) with established infection and 80% of MSM with acute or established HIV infection.12,23 It is uncertain whether other POC tests perform substantially differently, as studies using these tests on frozen specimens from persons with early infection have conflicting results.12,22,24,25
In 2010, we began a prospective cross-sectional study to compare the ability of different HIV tests to detect early infection in Seattle MSM, a population with high incidence and frequent testing. Previous studies suggest persons might prefer POC testing over venipuncture and laboratory-based testing18,26,27 and oral fluid over fingerstick specimen collection.18,28 We surveyed subjects to determine preferences in this population and evaluate the relative importance of specimen collection method (oral fluid, fingerstick, or venipuncture), turnaround time, and perceived test accuracy.
MSM and transgender persons were recruited into the main study at the Public Health—Seattle & King County Sexually Transmitted Disease Clinic, Gay City Health Project Wellness Center (community-based organization), and University of Washington Primary Infection Clinic (research clinic). Persons were eligible if they were HIV negative, reported sex with a man in the preceding year, could read and write in English, and had not participated in the study within 3 months. The University of Washington Institutional Review Board approved this study, and all subjects gave verbal consent.
Study procedures included 1 POC test performed on oral fluids (OraQuick) and 2 or 3 POC tests performed on fingerstick whole blood specimens: OraQuick (5 μL), Uni-Gold Recombigen HIV Test (Uni-Gold, Trinity Biotech, Dublin, Ireland, 50 μL), and Determine HIV-1/2 Ag/Ab Combo (Determine, Alere Inc., Scarborgouh, ME, 50 μL). Determine is not currently Food and Drug Administration (FDA)–approved and not available for sale in the United States; devices were provided by the manufacturer for investigational use 10 months after study enrollment began. We selected these tests because OraQuick is the predominant POC test used in Seattle, Uni-Gold's technology might make it more sensitive during early infection,29,30 and Determine is an antigen–antibody combination assay that can detect p24 antigen and incorporates principles of third-generation EIAs for antibody detection. POC tests were performed on specimens collected from separate fingersticks to obtain recommended specimen volumes, perform each test as directed, and ensure study validity.
Study counselors provided all POC test results. Serum specimens from subjects with negative POC results were sent for EIA and pooled NAAT as previously described12 with the following changes: we used the Genetic Systems HIV-1/HIV-2 Plus O EIA (BioRad Laboratories, Hercules, CA), and EIA-negative specimens were combined into 27-specimen pools using a 3 × 3 × 3 matrix31 for testing with the Abbott RealTime HIV-1 RNA assay (Abbott Molecular Inc, Des Plaines, IL). Subjects with reactive fingerstick test results had serum sent for confirmatory testing, CD4+ T-cell count, and HIV RNA level; and an appointment was scheduled to provide results, partner services, and linkage to care. Subjects received $20 for participation in the main study, which is ongoing.
The first 1000 subjects enrolled at the Public Health Sexually Transmitted Disease Clinic and Gay City Wellness Center were asked to complete an anonymous self-administered written survey that was not linked to clinic records. During study recruitment and testing, subjects were informed about technologies and test characteristics, including estimated window periods.32 Because the primary objective of the main study is to compare window periods of POC tests, subjects were told that antibodies become detectable approximately 1 month after HIV acquisition but it may take up to 3 months before POC tests can detect antibodies. Subjects were told that p24 antigen is present by the time of peak viremia and symptom onset (approximately 2 weeks after acquisition), but it is not known when Determine could detect antigen.
After completion of POC testing and post test counseling, HIV-negative subjects were asked individually to rate tests on a scale of 1 to 5 based on their preference for the specimen collection method. They then gave each test a single score for trust (from 1 to 5) based on their personal weighting of previously described test characteristics (specimen collection method, amount of specimen required, processing time, POC versus laboratory-based testing, and expected window period) and the timing of their visit relative to recent risk. The protocol did not specify additional information to be provided at this time. Finally, subjects were asked to select the one test they would choose, taking all factors into account, if they could have only one HIV test that day.
Between February 22, 2010, and July 31, 2011, 1000 subjects were enrolled. Forty-two (4.2%) subjects were newly diagnosed with HIV infection. Thirty-two (3.2%) HIV-infected subjects had concordantly reactive POC test results, and 3 (0.3%) HIV-infected subjects had at least 1 reactive and 1 nonreactive test result. One (0.1%) subject had nonreactive results on all POC tests (including Determine) but a reactive EIA. Six (0.6%) subjects were acutely infected (EIA negative/NAAT positive); the 1 subject tested after Determine was incorporated into study procedures had a reactive p24 antigen result.
Of 958 HIV-negative subjects, 490 (51%) completed the survey. Mean scores for preference for specimen collection methods (Fig. 1) were as follows: OraQuick (oral fluids) 4.2, OraQuick (fingerstick) 3.8, Uni-Gold (fingerstick) 3.6, Determine (fingerstick) 3.8, EIA (venipuncture) 3.3, and NAAT (venipuncture) 3.4. Mean scores for trust were as follows: OraQuick (oral fluids) 2.8, OraQuick (fingerstick) 4.0, Uni-Gold 4.0, Determine 3.9, EIA 4.7, and NAAT 4.9.
Among subjects surveyed before study procedures included Determine, 128 (49%, 95% confidence interval: 42% to 55%) of 263 subjects chose NAAT as the 1 test they would select, 49 (19%) chose OraQuick (fingerstick), 38 (14%) chose Uni-Gold, 29 (11%) chose EIA, and 19 (7%) chose OraQuick (oral fluids). Among 120 subjects surveyed after inclusion of Determine, 55 (46%, 95% confidence interval: 37% to 55%) chose NAAT, 18 (15%) chose Uni-Gold, 11 (9%) chose OraQuick (fingerstick), 9 (8%) chose EIA, and 8 (7%) chose OraQuick (oral fluids). Determine was selected by 19 (16%) subjects, and others voiced doubts because this test is not yet FDA approved.
As in other studies, MSM we surveyed preferred less invasive collection methods. However, they expressed greater trust in test results from fingerstick whole blood and venipuncture specimens. Other factors, including concerns about the window period, were apparently more important than preferences for collection method and immediacy of test results because nearly half of subjects opted for venipuncture and NAAT when asked to choose one test.
Our study has several limitations, including the fact that information provided could have influenced responses, and conversations during pretest counseling likely varied by client. Due to our selection bias, these findings may only be applicable to persons who have previously tested, as persons who have never tested often express preferences for oral fluid testing.26 Our results might also not apply to populations with less knowledge about tests or low-incidence settings where testing during early infection is infrequent. However, we believe these results are relevant for MSM in cities similar to Seattle. More than 90% of Seattle MSM have previously tested,33 and knowledge of pooled NAAT is high (Dr. Joanne Stekler, MD, MPH, unpublished data, July 2011). Our findings suggest that programs for MSM should offer combination testing, for example, POC testing plus pooled NAAT, to accomplish goals of client acceptance and early detection. Strategies in other settings might vary depending on whether programs aim to increase testing frequency34,35 (requiring tests able to detect recent infection) or lower barriers among untested populations (favoring less invasive methods).
Antigen–antibody combination assays (fourth-generation immunoassays) can detect acute HIV infection, have shorter turnaround times compared with NAAT, and will likely affect how we contemplate these trade-offs.12,34 Two laboratory-based fourth-generation assays are approved for use in the United States. If POC fourth generation assays prove to be accurate in populations such as ours and obtain FDA-approval, preferences could change.
As public health programs expand testing as part of the National HIV/AIDS Strategy, we must increase access to tests that are not only highly sensitive and specific but also account for client preferences. Validating measurements to assess these preferences deserves further attention through study of patient-centered outcomes. In high HIV incidence populations like ours, currently approved POC tests are inadequate, failing to detect 20% of HIV-infected persons in our studies, and must be supplemented with pooled NAAT or fourth-generation assays12,36,37 that are cost-effective when targeted.38 More importantly, we cannot miss opportunities to diagnose these 20%, the most infectious persons, who have already walked through our doors for testing. Thankfully, our clients agree that the best tests are worth the wait.
The authors would like to thank all of the study participants and the study counselors at the Gay City Health Project Wellness Center. The authors would also like to thank Heather Baldwin, MPH, for database management and other assistance.
1. Branson BM, Handsfield HH, Lampe MA, et al.. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55:1–17; quiz CE11–CE14.
2. Fiebig EW, Wright DJ, Rawal BD, et al.. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17:1871–1879.
3. Wawer MJ, Gray RH, Sewankambo NK, et al.. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005;191:1403–1409
4. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS. 2006;20:1447–1450.
5. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis. 2008;198:687–693.
6. Yerly S, Vora S, Rizzardi P, et al.. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS. 2001;15:2287–2292.
7. Pao D, Fisher M, Hue S, et al.. Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. Aids. 2005;19:85–90.
8. Brenner BG, Roger M, Routy JP, et al.. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis. 2007;195:951–959.
9. Jacquez JA, Koopman JS, Simon CP, Longini IM Jr. Role of the primary infection in epidemics of HIV infection in gay cohorts. J Acquir Immune Defic Syndr. 1994;7:1169–1184.
10. Koopman JS, Jacquez JA, Welch GW, et al.. The role of early HIV infection in the spread of HIV through populations. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:249–258.
11. Xiridou M, Geskus R, de Wit J, et al.. Primary HIV infection as source of HIV transmission within steady and casual partnerships among homosexual men. Aids. 2004;18:1311–1320.
12. Stekler JD, Swenson PD, Coombs RW, et al.. HIV testing in a high-incidence population: is antibody testing alone good enough? Clin Infect Dis. 2009;49:444–453.
13. Pilcher CD, Fiscus SA, Nguyen TQ, et al.. Detection of acute infections during HIV testing in North Carolina. N Engl J Med. 2005;352:1873–1883.
14. Facente SN, Pilcher CD, Hartogensis WE, et al.. Performance of risk-based criteria for targeting acute HIV screening in San Francisco. PLoS ONE. 2011;6:e21813.
15. Priddy FH, Pilcher CD, Moore RH, et al.. Detection of acute HIV infections in an urban HIV counseling and testing population in the United States. J Acquir Immune Defic Syndr. 2007;44:196–202.
16. Patel P, Klausner JD, Bacon OM, et al.. Detection of acute HIV infections in high-risk patients in California. J Acquir Immune Defic Syndr. 2006;42:75–79.
17. Hutchinson AB, Branson BM, Kim A, et al.. A meta-analysis of the effectiveness of alternative HIV counseling and testing methods to increase knowledge of HIV status. AIDS. 2006;20:1597–1604.
18. Spielberg F, Branson BM, Goldbaum GM, et al.. Choosing HIV counseling and testing strategies for outreach settings: a randomized trial. J Acquir Immune Defic Syndr. 2005;38:348–355.
19. Kuun E, Brashaw M, Heyns AD. Sensitivity and specificity of standard and rapid HIV-antibody tests evaluated by seroconversion and non-seroconversion low-titre panels. Vox Sang. 1997;72:11–15.
20. Samdal HH, Gutigard BG, Labay D, et al.. Comparison of the sensitivity of four rapid assays for the detection of antibodies to HIV-1/HIV-2 during seroconversion. Clin Diagn Virol. 1996;7:55–61.
21. Beelaert G, Vercauteren G, Fransen K, et al.. Comparative evaluation of eight commercial enzyme linked immunosorbent assays and 14 simple assays for detection of antibodies to HIV. J Virol Methods. 2002;105:197–206.
22. Owen SM, Yang C, Spira T, et al.. Alternative algorithms for human immunodeficiency virus infection diagnosis using tests that are licensed in the United States. J Clin Microbiol. 2008;46:1588–1595.
23. Stekler J, Wood RW, Swenson PD, et al.. Negative rapid HIV antibody testing during early HIV infection. Ann Intern Med. 2007;147:147–148.
24. Louie B, Wong E, Klausner JD, et al.. Assessment of rapid test performances for HIV antibody detection in recently infected individuals. J Clin Microbiol. 2008;46:1494–1497.
25. Masciotra S, McDougal J, Feldman J, et al.. Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections. J Clin Virol. 2011;52:S17–S22.
26. Chen MY, Bilardi JE, Lee D, et al.. Australian men who have sex with men prefer rapid oral HIV testing over conventional blood testing for HIV. Int J STD AIDS. 2010;21:428–430.
27. Spielberg F, Branson BM, Goldbaum GM, et al.. Overcoming barriers to HIV testing: preferences for new strategies among clients of a needle exchange, a sexually transmitted disease clinic, and sex venues for men who have sex with men. J Acquir Immune Defic Syndr. 2003;32:318–327.
28. Gaydos CA, Hsieh YH, Harvey L, et al.. Will patients “opt in” to perform their own rapid HIV test in the emergency department? Ann Emerg Med. 2011;58:S74–S78.
29. Ketema F, Zink HL, Kreisel KM, et al.. A 10-minute, US Food and Drug Administration-approved HIV test. Expert Rev Mol Diagn. 2005;5:135–143.
30. Louie B, Wong E, Klausner JD, et al.. Assessment of rapid tests for detection of human immunodeficiency virus-specific antibodies in recently infected individuals. J Clin Microbiol. 2008;46:1494–1497.
31. Goldsmith J. High throughput donor plasma NAT screening assay applied to acute HIV detection in a public health setting. Presented at: 2007 HIV Diagnostics Conference; December 5-7, 2007; Atlanta, GA. [oral #3]; 2007.
32. Stekler J, Maenza J, Stevens CE, et al.. Screening for acute HIV infection: lessons learned. Clin Infect Dis. 2007;44:459–461.
33. Brewer DD, Golden MR, Handsfield HH. Unsafe sexual behavior and correlates of risk in a probability sample of men who have sex with men in the era of highly active antiretroviral therapy. Sex Transm Dis. 2006;33:250–255.
34. Helms DJ, Weinstock HS, Mahle KC, et al.. HIV testing frequency among men who have sex with men attending sexually transmitted disease clinics: implications for HIV prevention and surveillance. J Acquir Immune Defic Syndr. 2009;50:320–326.
35. HIV testing among men who have sex with men–21 cities, United States, 2008. MMWR Morb Mortal Wkly Rep. 2011;60:694–699.
36. Pandori MW, Hackett J Jr, Louie B, et al.. Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting. J Clin Microbiol. 2009;47:2639–2642.
37. Patel P, Mackellar D, Simmons P, et al.. Detecting acute human immunodeficiency virus infection using 3 different screening immunoassays and nucleic acid amplification testing for human immunodeficiency virus RNA, 2006–2008. Arch Intern Med. 2010,170:66–74.
38. Hutchinson AB, Patel P, Sansom SL, et al.. Cost-effectiveness of pooled nucleic acid amplification testing for acute HIV infection after third-generation HIV antibody screening and rapid testing in the United States: a comparison of three public health settings. PLoS Med. 2010;7:e1000342.